Lymphoblastic Lymphoma (LBL)

Lymphoblastic lymphoma (LBL) is an aggressive non-Hodgkin lymphoma that develops from immature lymphoid cells. It is mainly divided into T-lymphoblastic lymphoma (T-LBL) and B-lymphoblastic lymphoma (B-LBL).

T-LBL is more common and often occurs in children, adolescents, and young men. It frequently involves the thymus and anterior mediastinum. B-LBL is less common and may involve lymph nodes or extranodal sites such as the skin or bones.

LBL and acute lymphoblastic leukemia (ALL) share similar cellular origins, immunophenotypic features, and molecular characteristics and are generally considered part of the same spectrum of precursor lymphoid neoplasms.

Clinically, the distinction is based mainly on the degree of bone marrow involvement and how the disease presents. Traditionally, disease with more extensive marrow involvement is classified as ALL, while disease presenting primarily as lymph node or extranodal masses with limited marrow involvement is classified as LBL.

The exact cause of LBL is not fully understood.

The disease develops through chromosomal, genetic, and molecular changes in immature T or B cells. These changes can disrupt normal cell growth, development, and death, allowing lymphoblasts to multiply and form tumors.

Different patients may have different genetic and molecular abnormalities. In most cases, it is not known what causes these changes, and there are no clearly established lifestyle factors that directly cause LBL.

Common Features of T-LBL

T-LBL often develops in the thymus and anterior mediastinum and may form a large mass in the chest. Symptoms may include:

• Cough

• Chest pressure or pain

• Shortness of breath or difficulty breathing

• Difficulty swallowing

• Swelling of the neck or arms

• Enlarged lymph nodes in the neck

• Fluid around the lungs or heart

If a mediastinal mass compresses the superior vena cava, it can cause superior vena cava syndrome, with symptoms such as swelling of the face, neck, or arms and difficulty breathing.

Common Features of B-LBL

B-LBL can present in a variety of ways, including:

• Painless enlarged lymph nodes

• Skin nodules or masses

• Bone pain or bone lesions

• Soft tissue masses

• Less commonly, involvement of the central nervous system or other sites

Other Symptoms

Some patients may also develop:

• Fever

• Drenching night sweats

• Unexplained weight loss

• Ongoing fatigue or weakness

• Loss of appetite

If the bone marrow is significantly involved, anemia, low platelet counts, or other blood abnormalities may occur.

Because LBL can grow rapidly and some patients have a high tumor burden, tumor lysis syndrome is also an important concern, particularly around the time of diagnosis and the start of treatment.

If LBL is suspected, diagnosis usually requires evaluation of tumor tissue or bone marrow, along with immunophenotypic, genetic, and molecular testing to determine the type and characteristics of the disease.

Imaging, blood tests, and evaluation of the central nervous system may also be used to determine the extent of the disease and guide treatment.

Biopsy

For patients with an enlarged lymph node, mediastinal mass, or other tumor site, enough tissue is usually obtained for pathological examination.

Immunohistochemistry and other tests help determine whether the lymphoma is of T-cell or B-cell origin and distinguish LBL from other types of lymphoma.

Bone Marrow Tests

Bone marrow aspiration and/or biopsy can determine whether the bone marrow is involved and help distinguish the clinical presentation of LBL from ALL.

Bone marrow samples may also undergo flow cytometry, chromosomal, genetic, and molecular testing.

Blood Tests

Blood tests can measure red blood cells, white blood cells, and platelets and assess liver and kidney function, electrolytes, uric acid, lactate dehydrogenase (LDH), and other markers.

These results help evaluate tumor burden, organ function, and the risk of complications such as tumor lysis syndrome.

PET/CT and Other Imaging Tests

CT or PET/CT can help evaluate involvement of the mediastinum, lymph nodes, and other organs and may be used for staging and treatment assessment.

For a mediastinal mass, imaging can also show the size of the tumor and whether it is compressing the airway, blood vessels, or other important structures.

MRI or other imaging tests may be used depending on the location of the disease.

Central Nervous System Evaluation

Depending on the treatment plan and individual situation, a lumbar puncture may be performed to examine cerebrospinal fluid for involvement of the central nervous system.

CNS evaluation can also help guide preventive or therapeutic CNS treatment.

Because LBL is closely related to ALL, both children and adults are generally treated with ALL-type, multi-phase combination therapy rather than the shorter chemotherapy regimens commonly used for many other non-Hodgkin lymphomas. ALL-based approaches have produced favorable long-term outcomes in children with LBL.

Treatment usually includes induction, consolidation/intensification, and maintenance therapy, together with CNS-directed treatment. The exact plan depends on factors such as T-LBL versus B-LBL, age, extent of disease, genetic and molecular features, and response to treatment.

Induction Therapy

Induction therapy is the first phase of treatment. Its main goal is to rapidly reduce the number of lymphoblasts and bring the disease into remission.

Several medications are usually given in combination, with close monitoring for infection, bleeding, tumor lysis syndrome, and other treatment-related complications.

Consolidation and Intensification Therapy

After remission is achieved, consolidation and intensification therapy are used to target lymphoma cells that may remain in the body and reduce the risk of relapse.

The medications and doses may differ from those used during induction and are selected based on risk level and response to treatment.

Maintenance Therapy

Many LBL treatment protocols include a longer period of maintenance therapy using lower-intensity medications to help reduce the risk of relapse.

The duration and medications used depend on the treatment protocol, age, and characteristics of the disease.

CNS-Directed Therapy

Because lymphoblastic neoplasms can involve the central nervous system, CNS prophylaxis is an important part of ALL-type treatment and is not limited to patients who already have CNS disease at diagnosis.

Intrathecal chemotherapy given through a lumbar puncture is commonly used, and some systemic medications also contribute to CNS protection.

Patients with confirmed CNS involvement may require more intensive CNS-directed treatment. Modern pediatric protocols generally try to avoid routine prophylactic cranial radiation whenever possible.

Targeted Therapy and Immunotherapy

Targeted therapies or immunotherapies may be used for selected patients depending on the type of LBL, genetic and molecular features, and previous treatments.

For example, nelarabine may be used in some patients with T-lineage lymphoblastic disease, particularly in selected treatment protocols or for relapsed/refractory disease. Targeted drugs may also be used when specific molecular abnormalities are present.

For B-lineage lymphoblastic disease, immune-based or cellular therapies directed at B-cell targets may also be considered in selected situations.

Hematopoietic Stem Cell Transplantation (HSCT)

Hematopoietic stem cell transplantation is not routinely required for every patient with newly diagnosed LBL.

For selected patients with high-risk disease, an inadequate response to treatment, or relapsed/refractory LBL, allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be considered after remission is achieved.

The decision depends on the type of disease, risk of relapse, response to treatment, previous therapies, age, overall health, and donor availability.

Radiation Therapy

With modern ALL-type systemic therapy and CNS-directed treatment, radiation therapy is not routinely used for most patients with LBL, particularly children.

Radiation may still be considered in selected situations, such as confirmed CNS involvement, persistent localized disease, or other specific clinical circumstances.

Clinical Trials

For patients with relapsed or refractory LBL, clinical trials may provide access to new medications, immunotherapies, cellular therapies, or other treatment strategies.